Skip to Main content Skip to Navigation
Journal articles

p53 dysregulation in B-cell malignancies: More than a single gene in the pathway to hell

Abstract : TP53 deletion or mutation is frequent in B-cell malignancies and is associated with a low response rate. We describe here the p53 landscape in B-cellmalignancies, from B-Acute Lymphoblastic Leukemia to Plasma Cell Leukemia, by analyzing incidence of gain or loss of function of actors both upstream and within the p53 pathway, namely MYC, RAS, ARF, MDM2, ATM and TP53. Abnormalities are not equally distributed and their incidence is highly variable among malignancies. Deletion and mutation, usually associated, of ATM or TP53 are frequent in Diffuse Large B-Cell Lymphoma and Mantle Cell Lymphoma. MYC gain, absent in post-GC malignancies, is frequent in B-Prolymphocytic-Leukemia,MultipleMyeloma and Plasma Cell Leukemias. RAS mutations are rare except in MM and PCL. Multiple Factorial Analysis notes that MYC deregulation is closely related to TP53 status. Moreover, MYC gain, TP53 deletion and RAS mutations are inversely correlated with survival. Based on this landscape, we further propose targeted therapeutic approaches for the different B-cell malignancies.
Document type :
Journal articles
Complete list of metadatas

Cited literature [162 references]  Display  Hide  Download

https://www.hal.inserm.fr/inserm-01493742
Contributor : Elizabeth Bernardo <>
Submitted on : Wednesday, March 22, 2017 - 8:22:02 AM
Last modification on : Thursday, June 18, 2020 - 5:48:01 PM

File

 Restricted access
To satisfy the distribution rights of the publisher, the document is embargoed until : jamais

Please log in to resquest access to the document

Identifiers

Citation

Benoit Tessoulin, Marion Eveillard, Anne Lok, David Chiron, Philippe Moreau, et al.. p53 dysregulation in B-cell malignancies: More than a single gene in the pathway to hell. Blood Reviews, Elsevier, 2017, [Epub ahead of print]. ⟨10.1016/j.blre.2017.03.001⟩. ⟨inserm-01493742⟩

Share

Metrics

Record views

257